Suraksha Diagnostic Ltd Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics Show Increasing Attractiveness

Suraksha Diagnostic Ltd currently trades at a price of ₹281.75, slightly down from its previous close of ₹284.50, with a day’s trading range between ₹280.70 and ₹282.85. The stock’s 52-week high stands at ₹353.65, while the low is ₹233.15, indicating a moderate volatility band over the past year.

Crucially, the company’s price-to-earnings (P/E) ratio has settled at 44.07, a figure that, while elevated compared to many sectors, is now considered attractive within its healthcare services peer group. This is a marked improvement from prior assessments that rated the valuation as merely fair. The price-to-book value (P/BV) ratio is 6.37, reflecting a premium valuation but consistent with the sector’s asset-light business models and growth prospects.

Enterprise value to EBITDA (EV/EBITDA) stands at 17.09, which, when compared with peers such as KMC Speciality Hospitals (18.41) and GPT Healthcare (13.79), positions Suraksha Diagnostic in a competitive valuation bracket. The EV to EBIT ratio of 30.05 and EV to sales of 5.24 further underline the company’s premium standing, though these multiples remain within reasonable bounds given its return metrics.

Return Ratios and Growth Indicators

Suraksha Diagnostic’s return on capital employed (ROCE) is a robust 15.80%, while return on equity (ROE) is 13.86%. These figures suggest efficient capital utilisation and profitability, supporting the premium valuation. The PEG ratio is reported as 0.00, which may indicate either a lack of consensus on earnings growth estimates or a data anomaly; however, the company’s growth trajectory remains a key consideration for investors.

Comparatively, peers such as GPT Healthcare and Asarfi Hospital exhibit very attractive valuations with lower P/E ratios of 26.15 and 20.53 respectively, and EV/EBITDA multiples below 14. This suggests that while Suraksha Diagnostic is attractive, there remain more aggressively valued opportunities within the sector.

Stock Performance Versus Sensex

Examining Suraksha Diagnostic’s recent returns relative to the Sensex reveals a mixed picture. Over the past week, the stock declined by 1.83%, underperforming the Sensex’s 0.98% drop. However, over the last month, Suraksha Diagnostic gained 6.46%, significantly outperforming the Sensex’s marginal 0.14% loss. Year-to-date, the stock has risen 5.05%, while the Sensex has declined 2.08%, indicating relative strength in the current calendar year.

Longer-term returns are less favourable, with the stock down 1.62% over the past year compared to the Sensex’s 9.81% gain. Data for three, five, and ten-year returns are unavailable for the stock, but the Sensex’s strong multi-year performance (36.80% over three years and 256.90% over ten years) sets a high benchmark for Suraksha Diagnostic to meet or exceed.

Mojo Grade Downgrade Reflects Caution Despite Valuation Appeal

Despite the improved valuation grade from fair to attractive, Suraksha Diagnostic’s overall Mojo Grade was downgraded from Hold to Sell on 11 August 2025, with a current Mojo Score of 47.0. This suggests that while the stock’s price multiples have become more appealing, other factors such as earnings quality, market sentiment, or operational risks have weighed on the overall recommendation.

The company’s market capitalisation grade remains low at 4, indicating a relatively smaller market cap compared to larger healthcare peers, which may contribute to liquidity concerns or higher volatility. Investors should weigh these considerations alongside valuation improvements when assessing the stock’s suitability for their portfolios.

Peer Comparison Highlights Relative Strengths and Weaknesses

Within the healthcare services sector, Suraksha Diagnostic’s valuation compares favourably to several peers but lags behind the most attractively priced companies. For instance, GPT Healthcare and Asarfi Hospital are rated very attractive with P/E ratios of 26.15 and 20.53 respectively, and EV/EBITDA multiples well below Suraksha’s 17.09. Conversely, companies like Gujarat Kidney and Lotus Eye Hospital trade at very expensive valuations, with P/E ratios of 98.49 and 397.91 respectively, underscoring Suraksha’s relative value proposition.

Some peers such as Hemant Surgical and Aashka Hospitals do not qualify for valuation attractiveness due to elevated multiples and weaker fundamentals. This peer context reinforces Suraksha Diagnostic’s position as an attractively valued option within a mixed competitive landscape.

Investment Implications and Outlook

Suraksha Diagnostic’s shift to an attractive valuation grade signals a potential entry point for investors seeking exposure to the healthcare services sector. The company’s solid return ratios and moderate premium multiples suggest underlying operational strength. However, the downgrade in overall Mojo Grade to Sell advises caution, highlighting the need for investors to consider broader risk factors beyond valuation alone.

Given the stock’s recent outperformance relative to the Sensex on a monthly and year-to-date basis, there is evidence of positive momentum. Yet, the underperformance over the past week and year indicates volatility and mixed investor sentiment. Prospective buyers should monitor upcoming earnings releases and sector developments to better gauge the sustainability of the valuation improvement.

Conclusion: Valuation Improvement Offers Opportunity Amid Caution

Suraksha Diagnostic Ltd’s recent valuation upgrade to attractive, supported by a P/E of 44.07 and EV/EBITDA of 17.09, marks a significant development for investors analysing healthcare services stocks. While the company’s returns on capital and equity are commendable, the downgrade in overall Mojo Grade to Sell and modest market cap grade temper enthusiasm.

Investors should consider Suraksha Diagnostic as a selectively attractive option within its sector, balancing valuation appeal against operational and market risks. The stock’s mixed performance relative to the Sensex further underscores the need for a nuanced approach, favouring those with a medium to long-term horizon and a tolerance for sector-specific volatility.

Continued monitoring of earnings trends, competitive positioning, and broader healthcare market dynamics will be essential to realising the potential benefits of the current valuation shift.

Unlock special upgrade rates for a limited period. Start Saving Now →